MedTrace Logo

Standard Therapy or Individualized Immunosuppression For Lowering Adverse Event Risk

NCT04473924 · Status: WITHDRAWN · Phase: PHASE2 · Type: INTERVENTIONAL

Last updated 2022-05-06

No results posted yet for this study

Summary

Infections are common and associated with poor outcomes as well as high financial costs after kidney transplantation. Identifying and implementing strategies to reduce infections after kidney transplantation is important for improving patient outcomes. This study seeks to determine the feasibility of body surface area-based dosing of mycophenolate compared to standard dosing of mycophenolate in a pilot randomized controlled trial.

Conditions

Interventions

DRUG

Mycophenolate Mofetil

Body surface area-based dosing of mycophenolate

DRUG

Mycophenolate Mofetil

Standard (fixed) dosing of mycophenolate

Sponsors & Collaborators

Principal Investigators

  • Elaine Ku, MD · University of California, San Francisco

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-07-31
Primary Completion
2023-01-31
Completion
2023-05-31
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04473924 on ClinicalTrials.gov